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Causal mediation analysisBackground: The high relapse andmortality rate of small-cell lung cancer (SCLC) fuels the need for epidemiologic
study to aid in its prevention.
Methods: We included 24 studies from the ILCCO collaboration. Random-effects panel logistic regression and
cubic spline regression were used to estimate the effects of smoking behaviors on SCLC risk and explore their
non-linearity. Further, we explored whether the risk of smoking on SCLC was mediated through COPD.
Findings: Significant dose–response relationships of SCLC risk were observed for all quantitative smoking vari-
ables. Smoking pack-years were associated with a sharper increase of SCLC risk for pack-years ranged 0 to ap-
proximately 50. The former smokers with longer cessation showed a 43%quit_for_5–9 years to 89%quit_for_≥20 years
declined SCLC risk vs. subjects who had quit smoking b5 years. Comparedwith non-COPD subjects, smoking be-
haviors showed a significantly higher effect on SCLC risk among COPD subjects, and further, COPD patients
showed a 1.86-fold higher risk of SCLC. Furthermore, smoking behaviors on SCLC riskwere significantlymediated
through COPD which accounted for 0.70% to 7.55% of total effects.
Interpretation: This is the largest pooling study that provides improved understanding of smoking on SCLC, and
further demonstrates a causal pathway through COPD that warrants further experimental study.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small cell lung cancer (SCLC) comprises approximately 15–18% of all
lung cancers worldwide (Fruh et al., 2013). SCLC is the most aggressive
subtype of lung cancer and is characterized by rapid doubling time, high
growth fraction, and early widespread metastasis (Kalemkerian et al.,
2013). Despite high response rates to initial treatment, SCLC usually re-
lapses and becomes refractory to treatment within one year. The medi-
an survival is 14–20 months for limited SCLC and 9–11 months for
extensive SCLC (Kalemkerian et al., 2013). These statistics highlight
the need for new tools to aid in diagnosis and prevention.
Smoking is themajor risk factor for SCLC (Pesch et al., 2012; Engeland
et al., 1996; Freedman et al., 2008). However, previous studies were lim-
ited in sample size and statistical power to estimate more precise effect
size of smoking on SCLC risk as well as the non-linear exposure–
response relationships, which have been thoroughly explored in the pre-
vious non-small cell lung cancer (NSCLC) studies (Zhai et al., 2014a, b).
Furthermore, smoking is also an independent risk factor for chronic ob-
structive pulmonary disease (COPD), which shares similar genetic and bi-
ological characteristics to lung cancer (Houghton, 2013; Roca et al., 2012;
Schwartz and Ruckdeschel, 2006; Young and Hopkins, 2011), while con-
comitant COPD has not been fully examined with regard to SCLC risk
(Purdue et al., 2007; Fan et al., 2011). Precise understanding of the associ-
ation between smoking, COPD, and SCLC using a large sample size will
shed light on its pathogenesis.
To address these knowledge gaps, we conducted a pooling analysis of
24 case–control studies in the International Lung Cancer Consortium
(ILCCO) that in total included 4346 SCLC cases and 37,942 cancer-free
controls. We examined: 1) exposure–response relationships between
SCLC risk and cigarette smoking indicators, including cumulative smoking,
age of initiation, and time since quitting smoking; 2) the association be-
tween physician diagnosis of COPD and SCLC risk; and 3) the interaction
and mediation effects of COPD and cigarette smoking on SCLC risk.
2. Methods
2.1. Ethics
Individual studies were approved by their respective ethics
committees.2.2. Study Population
This pooled analysis comprised data from the ILCCO collaboration
(http://ilcco.iarc.fr), which was established in 2004 to share data
among ongoing lung cancer studies (Hung et al., 2008). We included
24 ILCCO studies that met the following criteria: 1) had histologically
confirmed SCLC cases; 2) used a structured questionnaire to evaluate
lifestyle; and 3) provided an intact study protocol. Among the 24 stud-
ies, two (Schottker et al., 2013; Goodman et al., 1998)were cohort stud-
ies. The remaining 22 had a case–control design, ten (Miller et al., 2002;
Muscat et al., 1995; Loriot et al., 2001; Lopez-Cima et al., 2012; Kim and
Hong, 2013; Ito et al., 2012; Lee et al., 2009; Ruano-Ravina et al., 2014;
Zhang et al., 2010; Park et al., 2005) were hospital-based, ten studies
(Kreienbrock et al., 2001; Landi et al., 2008; Luce and Stucker, 2011;
Schwartz et al., 2009; Field et al., 2005; Heck et al., 2009; Sevilya et al.,
2014; Cote et al., 2012; Hashibe et al., 2006; Wang et al., 2014) were
population-based, and the other two (Yang et al., 2005; Brenner et al.,
2010) were mixed case–control studies. The included studies were per-
formed in North America (Goodman et al., 1998; Miller et al., 2002;
Muscat et al., 1995; Park et al., 2005; Schwartz et al., 2009; Heck et al.,
2009; Hashibe et al., 2006;Wang et al., 2014; Yang et al., 2005; Brenner
et al., 2010), Europe (Schottker et al., 2013; Loriot et al., 2001;
Lopez-Cima et al., 2012; Lee et al., 2009; Kreienbrock et al., 2001;
Landi et al., 2008; Luce and Stucker, 2011; Field et al., 2005; Cote et al.,
2012; Ruano-Ravina et al., 2004), and Asia and Oceania (Lopez-Cima
et al., 2012; Kim and Hong, 2013; Ruano-Ravina et al., 2014; Heck
et al., 2009). Each included study was approved by the institutional re-
view boards of the respective institutions, and each participant provid-
ed informed consent.
2.3. Case Ascertainment
Incident lung cancer cases were diagnosed pathologically and verified
through reviewofmedical records (Schottker et al., 2013; Goodman et al.,
1998; Miller et al., 2002; Muscat et al., 1995; Loriot et al., 2001; Kim and
Hong, 2013; Ito et al., 2012; Lee et al., 2009; Ruano-Ravina et al., 2014;
Park et al., 2005; Kreienbrock et al., 2001; Landi et al., 2008; Schwartz
et al., 2009; Field et al., 2005;Wang et al., 2014; Yang et al., 2005; Brenner
et al., 2010; Etzel et al., 2006), linkage to cancer registries (Lopez-Cima
et al., 2012; Ito et al., 2012; Luce and Stucker, 2011; Schwartz et al.,
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2014; Brenner et al., 2010), or linkage to mortality registries
(Goodman et al., 1998; Field et al., 2005). Histology information
was ascertained based on the ICD for Oncology morphology codes
or by individual studies. The proportion of SCLC over total lung can-
cers ranged from 4 to 24%. The cases that were staged as either lim-
ited stage or extensive stage were combined in the analysis.
Among the ten studies that had COPD diagnostic information
(Table S1), the baseline questionnaires listed chronic emphysema,
bronchitis, and/or COPD, and other lung disorders such as asthma
and tuberculosis. Each subject was asked to self-report whether he/
she was ever diagnosed by a physician of chronic bronchitis, emphy-
sema, or COPD, categorized as present or absent. Subjects who had
physician diagnosed chronic emphysema, bronchitis, and/or COPD
were defined as having COPD. One study also validated the COPD di-
agnosis with pulmonary function tests (Yang et al., 2005).
2.4. Smoking and Other Factors
All studies collected information on lifetime history of cigarette
smoking, including age of initiation of smoking, duration, intensity,
and time since quitting for former smokers. To explore the non-linear
association between smoking and SCLC, we generated common cate-
gorical variables related to smoking status (never smoker defined as
no cumulative smoking, current smoker defined as cumulative smoking
of any amount plus time since quitting smoking less than or equal to
1 year, and former smoker defined as smokers who had quit more
than 1 year before diagnosis or interview), daily smoking intensity
(1–9, 10–19, 20–29, 30–39, and 40 or more cigarettes/day), smoking
duration (1–19, 20–29, 30–39, 40–49, and 50 or more years), and life-
time cumulative smoking (1–19, 20–39, 40–59, 60–79, and 80 or
more pack-years; one pack-year being equivalent to 20 cigarettes/day
smoked during 1 year). Former smokers were further categorized ac-
cording to age of smoking initiation (less than 15 years, 15–20, 20–25,
25–30, or more than 30 years) and time since quitting (b5, 5–9,
10–19, or 20 or more years).
Other variables included in the pooled analysis were gender, age
at diagnosis or interview, geographical region (North America,
Europe, and Asia and Oceania), self-reported race (Asian, Black,
White, Hawaiian, Hispanic, Other), family history of lung cancer
(yes, no), and education level (non, elementary, vocational, postsec-
ondary, university).
2.5. Statistical Analysis
2.5.1. Non-linear Exposure–Response Relationships of Smoking Behaviors
on SCLC
The odds ratios (ORs) of SCLC and their 95% confidence intervals
(95% CIs) for daily smoking intensity, duration of smoking, lifetime
cumulative smoking, age of smoking initiation, and time since quit-
ting were estimated using random-effects panel logistic regression
(Conway, 1990). This multilevel model takes account of the variation
among studies (panels), and study heterogeneity, during model
fitting. The ρ, ranging from 0 to 1, represents the proportion of the
total variance contributed by the panel (study)-level variance com-
ponent. When ρ is zero, the panel-level variance component is neg-
ligible, and the estimators from the panel logistic regression are no
different from that from the traditional logistic regression. Age at diag-
nosis and gender were adjusted for in all the regression models. Trends
of SCLC risk across smoking categories were evaluated byfitting the cat-
egorical smoking variables into anordinal regressionmodel (Armstrong
and Sloan, 1989). To better visualize the exposure–response relation-
ship, we plotted cumulative smoking, age of smoking initiation, and
time since quitting smoking with the SCLC risks using estimates from
restricted cubic spline models (Hastie and Tibshirani, 1995; Campbell,
1996). The non-linear association was explored by applying thelikelihood test to compare the spline model to its nested linear model.
Subgroup analyses were performed stratified by COPD status, gender,
study area (Caucasian-dominated areas vs. non-Caucasian dominated
areas), source of controls (hospital-based controls vs. population-
based controls), and 1st degree family history of lung cancer (yes vs.
no), and the difference of risk effects between subgroups was evaluated
by including the interaction term of smoking and stratifying variable
into the model.
2.5.2. Interaction and Mediation Analyses
The associations between cumulative smoking and SCLC risk
were further tested in subgroups with and without preexisting
COPD. We conducted the Wald test for effect modification from
COPD by adding an interaction term. It is well-established that
smoking is the risk to both COPD and SCLC, and COPD is a risk factor
to SCLC. To explore whether the effect of smoking on the risk of SCLC
is mediated through COPD, the VanderWeele's mediation analysis
was performed (VanderWeele and Vansteelandt, 2010). The
smoking effect on SCLC was decomposed to two parts: the indirect
effect which represents the effect of smoking is mediated through
COPD and the direct effect which represents the effect of smoking
on SCLC by pathways other than COPD. To obtain direct and indirect
effects of smoking on SCLC risk, ORs for mediation analysis in the
case–control setting were calculated by combining the regression
of COPD and the regression of SCLC risk (VanderWeele and
Vansteelandt, 2010; VanderWeele et al., 2012). The proportion me-
diated was obtained by ORd× (ORi − 1) / (ORd × ORi − 1), where
ORd is the direct effect odds ratio and ORi is the indirect effect odds
ratio (Campbell, 1996).
All tests were two-sided and evaluated using SAS software (version
9·4; SAS Institute, Cary, NC) or STATA statistical package (Version 14;
Stata Corp. LP, College Station, TX, USA). A P-value of less than 0.05
was considered statistically significant.
3. Results
3.1. Characteristics of Study Populations
In the 24 studies with recruitment initiated since 1969, 4346 SCLC
patients and 37,942 non-SCLC controls were identified (Table S1).
Among ten studies with available COPD status, 1543 COPD and 14,665
non-COPD subjects were further analyzed to explore stratified and me-
diation effects. Demographic characteristics are summarized in Table 1.
SCLC patients were significantly older, male-predominant, less educat-
ed, and more commonly had a family history of lung cancer than their
respective controls (P b 0.01). For smoking behaviors, the proportions
of current smokers/former smokers, the amount of lifetime cumulative
smoking pack-years, smoking duration, and smoking intensity (ciga-
rettes per day) in SCLCs or COPDs were significantly higher than in
their respective controls, while the time since quitting smokingwas sig-
nificantly lower than that in controls (P b 0.01). The frequency of COPD
diagnosis was higher among SCLC cases (20.6%) than controls (7.6%)
(P b 0.001).
3.2. Association of Smoking Behaviors With SCLC Risk
Former smokers had a significantly higher risk on SCLC vs. non-
smokers (OR, 6.21, 95% CI 5.21–7.41, P b 0.001) while a much higher
risk existed among current smokers vs non-smokers (OR, 26.72, 95%
CI 22.54–31.68, P b 0.001) (Table 2). A statistically significant dose–
response for SCLC risk was observed for all quantitative smoking var-
iables (Table 2). Cumulative smoking intensity (smoking pack-
years) was associated with increased risk of SCLC vs. non-smokers
in a significant dose–response manner [ORs ranged from 4.33 for
those who had pack-years b 20 to 69.03 for those who had pack-
years ≥ 80, P for trend (Ptrend) b 0.001]. Smoking intensity had a
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34.49 ≥ 40_cigarettes-per-day, Ptrend b 0.001), as well as smoking duration
(ORs ranged from2.37 b 20_years to 48.80 ≥ 50_years, Ptrend b 0.001), and age
of initiation (ORs from 7.09smoking_after_30 to 24.04smoking_before_15,
Ptrend b 0.001). The former smokers with longer cessation showed a
considerably decreased risk on SCLC risk in a dose–response trend vs.
subjects who had quit smoking for less than 5 years [OR for those
who had quit for 5–9 years (OR5–9), 0.57, 95% CI 0.45–0.73; OR10–19,
0.28, 95% CI 0.23–0.36; OR ≥ 20, 0.11, 95% CI 0.09–0.14; Ptrend b 0.001].
The sensitivity analysis yielded similar results with further adjust-
ment for study areas (Caucasian-dominated areas vs. non-
Caucasian-dominated areas), source of controls (hospital-based vs.
population-based), and family history of lung cancer (yes vs. no)
(Table 2).3.3. Stratified Analyses of Smoking Behaviors on SCLC Risk
Further, we performed the stratified analyses by COPD, gender, eth-
nicity, source of control, and 1st degree family history of lung cancer. All
the smoking variables showed a higher effect on SCLC risk in COPD sub-
group than those in non-COPD subjects with significance or borderline
significance except for time since quitting smokingwhichwas probably
due to insufficient sample size (Table S2). Male smokers had a trend of
stronger dose–response on SCLC risk than that in female but with a lack
of statistical significance (Table S3). Smoking variables in Caucasian-
dominated populations showed stronger effects on SCLC risk than
those in non-Caucasian dominant populations (Table S4). No statistical
significancewas observed for time since quitting smoking probably due
to insufficient sample size from non-Caucasian populations (Table S4).
Further, stratified analyses by control type showed a trend of higher ef-
fects of smoking behaviors on SCLC risk in the studies with population-
based controls than those in the studies with hospital-based controls
(Table S5). Furthermore, in stratified analysis by family history of lung
cancer, smoking behaviors showed a trend of, but non-significant,
stronger effects in subjects with family history of lung cancer than the
others (Table S6).Table 1






Age, mean (SD) 61.2(10.5)
Gender (female), n (%) 1371(31.6)
Ethnicity (Caucasian), n (%) 2310(87.1)
Education (greater than university), n (%) 487(15.9)





Smoking pack-years, mean (SD) 46.8(27.9)
Smoking intensity (cigarettes per day), mean (SD) 24.1(12.4)
Smoking duration (years), mean (SD) 39.1(10.6)
Age of initiation (years), mean (SD) 18.1(4.9)
Age of cessation (years), mean (SD) 55.9(10.9)
Time since quitting smoking among former smokers (years), mean (SD) 3.9(7.7)
Values are presented as n (%) for categorical data or mean(standard deviation [SD]) for contin
variableswere compared by Student t-test between groups/subgroups. The quantitative smokin
cer; COPD: chronic obstructive pulmonary disease.
a A subset of 10 studies that have reported COPD status in both case and control including the Re
b P-value ≤ 0.01 of COPD vs. non-COPD among SCLC cases.
c P-value b 0.01 of SCLC vs. non-SCLC among overall samples.
d P-value b 0.01 of COPD vs. non-COPD among non-SCLC subjects.3.4. Non-linear Exposure–Response Relationships
Further, non-linear exposure–response relationships of smoking
pack-years and time since quitting smoking were explored using re-
stricted cubic spline regressionmodel (Fig. 1). The SCLC risk for cumula-
tive smoking pack-years revealed an upward spline with a knot at
approximately 50 pack-years (Pnon-linear b 0.001); the slope of the first
segment was larger than that of the second segment (Fig. 1a). The re-
sults were consistent in the subgroup analyses stratified by COPD status
(Fig. 1b for non-COPD, 1c for COPD), by gender (Fig. 1d for male, 1e for
female), and study area (Fig. 1f for Caucasian-dominated areas, Fig. 1g
for non-Caucasian-dominated areas). In contrast, there were signifi-
cantly decreasing trends between time since quitting smoking and
SCLC risk among former smokers (Fig. 1h) which obtained consistent
results among the subgroup analyses (Fig. 1i–m). We were not able
to perform the cubic spline analysis among the former smokers in
studies from non-Caucasian-dominated areas due to insufficient
cases recruited.3.5. Smoking Effect on SCLC Mediated Through COPD
Smoking behaviors were positively associated with COPD risk
(Table S7). COPD status was independently associated with SCLC risk
(OR, 1.86, 95% CI 1.61–2.16, P b 0.001) with adjustment for age, gender,
and smoking pack-years. Furthermore, to explore whether the associa-
tion between smoking and SCLC risk was mediated through COPD, we
performed a series of mediation analyses (Table 3). A statistically signif-
icant indirect effect on SCLC risk mediated through COPD was observed
for former smokers [ORindirect, 1.03, P b 0.001; proportion mediated
(%M), 3.57%] or current smokers (ORindirect, 1.06, P b 0.001; %M, 5.86%),
smoking pack-years (ORindirect per SD, 1.03, P b 0.001; %M, 4.99%),
smoking intensity (ORindirect per SD, 1.01, P b 0.001; %M, 2.52%), smoking
duration (ORindirect per SD, 1.05, P b 0.001; %M, 7.55%), and time since
quitting smoking (ORindirect per SD, 0.98, P=0.005; %M, 0.70%). Overall,










503(100) 1940 (100) 35,944 (94.7) 1040(100) 12,725 (100)
1995 (5.3)
63.9(9.4) 60.6 (10.7)b 58.8 (12.7)c 61.3(10.3) 58.1 (12.5)d
193(38.4) 601 (31.0)b 14,269 (37.6)c 373(35.9) 5262 (41.4)d
299(59.4) 1000 (51.6)b 23,507 (85.2)c 427(41.1) 7442 (58.5)d
82(20.0) 260 (16.8) 7047 (32.1)c 228(27.6) 3733 (43.9)d
25(19.5) 83 (17.5) 1435 (9.8)c 67(17.3) 764 (12.2)d
b c d
3(0.8) 101 (7.1) 13,613 (37.5) 278(28.7) 5075 (45.0)
114(31.2) 332 (23.4) 13,002 (35.8) 400(41.3) 3875 (34.4)
249(68.0) 987 (69.5) 9696 (26.7) 291(30.0) 2332 (20.7)
53.7(31.5) 43.3 (27.1)b 27.6 (24.2)c 32.7(27.7) 24.2 (23.4)d
25.6(13.0) 23.0 (12.1)b 18.7 (12.2)c 19.3(12.5) 18.0 (12.4)d
42.0(10.4) 38.9 (10.4)b 31.2 (14.3)c 39.7(11.7) 32.7 (14.4)d
18.0(4.5) 18.4 (4.8)b 18.8 (5.7)c 18.6(5.2) 18.8 (5.4)d
58.9(9.6) 53.9 (10.7)b 46.0 (14.8)c 47.5(13.3) 42.8 (14.5)d
4.0(8.0) 3.5 (7.4)b 13.8 (13.3)c 11.6(13.0) 12.5 (13.1)d
uous variables. The categorical variables were tested by Fisher's exact test and continuous
g variableswere summarized among former or current smokers. SCLC: small cell lung can-
SoLuCENT study, NELCS, FHS, CAPUA,MSH-PMH, SLRI, ICARE,Mayo Clinic, MGH, andHMGU.
Table 2
Smoking behaviors and the risk of SCLC.
Variable NSCLC/Nnon-SCLC Overall analysis Sensitivity analysisa
OR (95% CI)b Z P ρc OR (95% CI)a Z P ρc
Smoking status 0.16 0.19
Never 166/13,613 1.00 (ref) \\ \\ 1.00 (ref) \\ \\
Former 987/13,002 6.21 (5.21,7.41) 20.36 0.000 6.13 (5.10,7.37) 19.32 0.000
Current 2510/9696 26.72 (22.54,31.68) 37.83 0.000 26.96 (22.57,32.21) 36.32 0.000
Trend test 48.06 0.000 46.24 0.000
Smoking pack-years 0.16 0.20
Never smokers 166/13,613 1.00 (ref) \\ \\
b20 462/9110 4.33 (3.61,5.19) 15.80 0.000 4.28 (3.51,5.21) 14.42 0.000
20–39 1365/6996 19.19 (16.23,22.69) 34.54 0.000 18.61 (15.49,22.36) 31.20 0.000
40–59 1063/3533 35.86 (30.12,42.71) 40.17 0.000 33.88 (27.93,41.09) 35.75 0.000
60–79 527/1275 55.04 (45.32,66.84) 40.43 0.000 57.91 (46.51,72.10) 36.29 0.000
≥80 474/889 69.03 (56.38,84.52) 41.00 0.000 73.91 (58.69,93.08) 36.58 0.000
Trend test 57.32 0.000 51.33 0.000
Smoking intensity (cigarettes per day) 0.16 0.19
Never smokers 166/13,613 1.00 (ref) \\ \\ 1.00 (ref) \\ \\
b10 246/4371 4.35 (3.55,5.34) 14.17 0.000 4.06 (3.26,5.05) 12.51 0.000
10–19 1142/6979 13.70 (11.56,16.24) 30.15 0.000 13.08 (10.88,15.73) 27.36 0.000
20–29 1307/6670 20.31 (17.14,24.08) 34.68 0.000 20.12 (16.70,24.24) 31.57 0.000
30–39 578/2154 29.93 (24.83,36.07) 35.68 0.000 31.67 (25.76,38.92) 32.83 0.000
≥40 609/1929 34.49 (28.56,41.65) 36.78 0.000 35.99 (29.15,44.45) 33.28 0.000
Trend test 48.01 0.000 43.96 0.000
Smoking duration (years) 0.12 0.10
Never smokers 166/13,613 1.00 (ref) \\ \\ 1.00 (ref) \\ \\
b20 100/4000 2.37 (1.83,3.07) 6.53 0.000 2.52 (1.90,3.34) 6.40 0.000
20–29 543/3635 14.67 (12.18,17.67) 28.33 0.000 16.04 (13.05,19.72) 26.36 0.000
30–39 1039/4645 25.54 (21.40,30.48) 35.89 0.000 28.89 (23.65,35.28) 32.97 0.000
40–49 1197/4259 37.43 (31.16,44.95) 38.76 0.000 41.92 (34.07,51.59) 35.30 0.000
≥50 561/1731 48.80 (39.60,60.12) 36.50 0.000 52.69 (41.73,66.54) 33.30 0.000
Trend test 46.09 0.000 42.50 0.000
Age of initiation (years) 0.14 0.10
Never smokers 165/13,612 1.00 (ref) \\ \\ 1.00 (ref) \\ \\
≥30 80/840 7.09 (5.32,9.46) 13.32 0.000 6.70 (4.92,9.13) 12.05 0.000
25–29 138/858 12.57 (9.79,16.15) 19.82 0.000 12.44 (9.49,16.30) 18.25 0.000
20–24 636/3592 14.17 (11.71,17.15) 27.22 0.000 13.58 (11.01,16.75) 24.36 0.000
15–19 1603/8826 15.74 (13.15,18.84) 30.07 0.000 15.48 (12.71,18.87) 27.16 0.000
b15 497/2049 24.04 (19.67,29.39) 31.04 0.000 25.30 (20.27,31.58) 28.56 0.000
Trend test 35.38 0.000 31.96 0.000
Time since quitting smoking among former smokers (years) 0.05 0.04
b5 199/718 1.00 (ref) \\ \\ 1.00 (ref) \\ \\
5–9 158/927 0.57 (0.45,0.73) 4.61 0.000 0.57 (0.45,0.72) 4.63 0.000
10–19 197/2092 0.28 (0.23,0.36) 11.08 0.000 0.28 (0.23,0.35) 11.16 0.000
≥20 149/3493 0.11 (0.09,0.14) 18.15 0.000 0.11 (0.09,0.14) 18.23 0.000
Trend test 19.40 0.000 19.49 0.000
a With further adjustment for family history of lung cancer (yes vs. no), study area (Caucasian-dominated areas vs. non-Caucasian-dominated areas), source of controls (hospital-based
vs. population-based).
b Odds ratio (OR), 95% confidence interval (95% CI), Z, and P-values were estimated using random-effects panel logistic regression by study center with adjustment for age and gender.
c The proportion of the total variance contributed by the panel (study)-level variance component. It is ranged from 0 to 1. The closer of ρ to 0 represents the less heterogeneity among
studies. When ρ is zero, the panel-level variance component is unimportant, and the panel estimator is no different from the pooled logistic estimator.
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To our knowledge, this is the largest study investigating the relation-
ship among multiple quantitative smoking risk factors, COPD, and risk
of SCLC (Pesch et al., 2012). The major strength of this study is its
large sample size, which allowed us to have greater power to detect
the exposure–response relationship of smoking behaviors, COPD, and
SCLC risk in more homogeneous subgroups, and the risks of smoking
mediated through COPD (Zhai et al., 2014a). Furthermore, the multi-
ethnic design makes this study generalizable to the other populations
(St Sauver et al., 2012). The pooling study also took advantage of the
well-planned questionnaires that collected data on detailed smoking
behaviors such as cumulative smoking, age since smoking initiation,
and time since quitting smoking, as well as COPD status.
Our study addressed the information gap regarding the non-linear
exposure-response relationships between the cigarette smoking behav-
iors, COPD, and risk of SCLC. SCLC risk rises sharply with the first
50 pack-years of cumulative smoking, and increases continuously with
further smoking. A similar steep slope with a subsequent leveling-off oflung cancer risk for intensity of smoking and a plateauing of the SCLC
risks by duration of smoking were seen in previous studies (Pesch et al.,
2012; Zhai et al., 2014a; Vineis et al., 2000). Findings of very high relative
risks for SCLC in smokers are in agreement with experimental findings
that more extensive damage triggers the regeneration of quiescent sub-
populations of cells (Li and Clevers, 2010). Those cells that are centrally
located in the lungs are possibly the cellular precursors of SCLC that
react to more extensive damage (Liu and Engelhardt, 2008; Liu et al.,
2006). The leveling-off association among extremely heavy and long-
term smokersmight be explained by a potential saturation effect, or com-
peting risks among heavy smokers (Vineis et al., 2000).
Juvenile initiated cigarette smoking would have over 15-fold higher
risk of SCLC in the following years compared with non-smokers. The
sensitivity analysis by further adjustment for smoking duration showed
a reduced magnitude of risk, which implies that the effect of smoking
initiation is, to some extent, dependent on the smoking duration,
while still retaining significance.
SCLC risk steadily decreased as years since smoking cessation in-
creased, which underscores the importance of quitting smoking as
Fig. 1. The dose–response relationship between smoking behaviors and the risk of SCLC. Smoking pack-years were explored on the non-linear dose–response relationship on SCLC risk
among all samples (a), or stratified by COPD status (b, c), by gender (d, e), or by study areas (f, g). Time since quitting smoking was also explored by cubic spline regressions for non-lin-
earity among all samples (h), or stratified by COPD status (i, j), by gender (k, l), or among Caucasian-dominated areas (m). Due to insufficient sample size, there was no subgroup analysis
done among non-Caucasian-dominated areas. The x-axis represents the quantitative smoking information while the y-axis represents the odds in loge scale.
1682 R. Huang et al. / EBioMedicine 2 (2015) 1677–1685early as possible. The risk remains 3.59 fold higher (95%CI 2.71–7.46, P b
0.001) after 20 years' cessation compared with never smokers. A possi-
ble mechanism for this long-term carcinogenic effect of smoking is thatFig. 2. A diagram of mediation model.cigarette smoke can exert a wide range of irreversible changes in lung
tissue that affect its function (Thorley and Tetley, 2007).
The risk of lung cancer in patients with COPD has long been
established (Zhai et al., 2014a; Purdue et al., 2007; Raviv et al.,
2011). However, most of the studies focused on the risk of overall
lung cancer or NSCLC, while the relationship with SCLC was rarely
explored or underpowered (Kato et al., 2011). Our analysis offers in-
sights suggesting that 86% of increased risk of SCLC occurs in persons
with COPD independent from smoking. Further, our study suggests
that smoking has a higher damaging effect on lungs among subjects
diagnosed of COPD than non-COPD subjects, which indicates a syner-
getic mechanism in lung cancer pathophysiology. This finding agrees
with that of our previous study of non-small cell lung cancer (Zhai
et al., 2014a). One biological explanation for this association be-
tween COPD and SCLC is that long-term pulmonary inflammation
from COPD damages lung tissue and produces free radicals that
may induce mutagenesis during tissue regeneration (Ballaz and
Mulshine, 2003). Another potential mechanistic explanation is that
Table 3
Causal mediation analysis of smoking behaviors, COPD, and the risk of SCLC.
Variable ORindirect (95% CI) P ORdirect (95% CI) P %M
Smoking status
Never vs former 1.03 (1.02, 1.05) 0.000 5.30 (4.84, 5.81) 0.000 3.57
Never vs current 1.06 (1.04, 1.09) 0.000 28.13 (23.41, 33.80) 0.000 5.86
Smoking pack-years
per SD (25.9) increment
1.03 (1.02, 1.04) 0.000 2.33 (2.22, 2.44) 0.000 4.99
Smoking intensity
per SD (13.2) increment
1.01 (1.01, 1.02) 0.000 1.63 (1.56, 1.71) 0.000 2.52
Smoking duration (years)
per SD (17.9) increment
1.05 (1.03, 1.07) 0.000 2.58 (2.35 2.84) 0.000 7.55
Age of initiation (years)
per SD (5.6) increment
0.99 (0.80, 1.01) 0.158 0.89 (0.82, 0.95) 0.001 7.49
Time since quitting smoking among former smokers
per SD (13.0) increment
0.98 (0.97, 0.99) 0.005 0.26 (0.22, 0.30) 0.000 0.70
Odds ratios (OR)were in per standard deviation (SD, among all samples) increment. The SDs of smoking pack years, smoking intensity, smoking duration, age of initiation, time since quit-
ting smoking among former smokers were 25.9 pack-years, 13.2 cigarettes per day, 17.9 years, 5.6 years, and 13.0 years, respectively.
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removal of harmful particles (Zhai et al., 2014b; Houtmeyers et al.,
1999). Other mechanisms associated with the presence of COPD
that might be associated with the inflammation and associated cyto-
kines, development of lung cancer includes alterations to cell cycle
regulation, shared genetic and epigenetic susceptibilities (Houghton,
2013). Furthermore, no study has previously investigated the role of
COPD as a causal mediator between smoking and SCLC. Our study dem-
onstrates that less than 10% of the smoking risk effect on SCLC is medi-
ated through COPD. Wang et al. reported one-third of the effect of
smoking behavior on lung cancermediated through COPD. The findings
indicate a histologically-different causal role of COPD among smoking
and lung cancer, which warrants further validation and experimental
study (Wang et al., 2010).
We acknowledge some limitations in our study. First, misclassifi-
cation of SCLC or COPD has to be considered since our study included
diverse countries in which different diagnostic criteria may apply. A
pathology comparability analysis was performed by Stang et al. in a
German case series; the agreement between pathologists was 94%
for SCLC, and lower in never smokers (Stang et al., 2006). Second,
studies included were lacking information on spirometry, and
underdiagnostics of COPD was thus significant among non-COPD
subjects, which is about 70% of the total population (Mannino
et al., 2000; Lamprecht et al., 2015; Bednarek et al., 2008). Due to
underdiagnosed COPD patients, risks of smoking behaviors among
non-COPD subgroups were, to some extent, overestimated. Howev-
er, physician-diagnosed COPD is compatible with spirometry-based
COPD for epidemiological studies (Straus et al., 2002; Eisner et al.,
2005; Murgia et al., 2014). A validation assessment also confirmed
that self-reported physician-diagnosed COPD correlates with high
rates of true COPD in medical records (Barr et al., 2002). Therefore,
such underdiagnosis of COPD contributes to the more conservative
results for the evaluation of the risk difference between COPD and
non-COPD. On the other hand, a more accurate COPD diagnostic
method will result in a higher stratified effect as well as stronger sta-
tistical power. Third, medication information of COPD patients was
also important to this association study. Inhaled corticosteroids
(ICS) are anti-inflammatory drugs that have proven benefits for
worsening COPD patients (Kew and Seniukovich, 2014), as well as
a decreased risk of lung cancer in a dose–response manner
(Parimon et al., 2007; Lee et al., 2013). Statins are also recognized
as powerful anti-inflammatory agents beyond low-density lipopro-
tein cholesterol reduction (Pruefer et al., 2002), which have a bene-
ficial role in COPD treatment including reduced risk of lung cancer
(Janda et al., 2009; van Gestel et al., 2009). Inclusion of the medica-
tion information in future study increases both statistical power
and clinical interpretation. Besides, the source of controls, SCLC
case ascertainment, COPD verification, geographical area, andrecruitment period could explain partial heterogeneity. Though we
detected a significant indirect effect of smoking on SCLC risk mediat-
ed by COPD, we were not able to determine the temporal relation-
ship between COPD and SCLC in this study, and reverse causality of
the pre-diagnosed stage of SCLC could thus possibly affect COPD de-
velopment as well.
5. Conclusion
This study emphasizes the non-linear association of smoking with
the relative risk of SCLC. The pattern is partially supported by prior
SCLC studies (Pesch et al., 2012; Vineis et al., 2000) and hypothesis-
generating experiments. Smoking also has a strong effect on COPD,
and COPD is an independent risk factor on SCLC, and further, a part of
smoking risk effect on SCLC is mediated through COPD. The mutually
shared genetic predisposition or common mechanistic pathway
among smoking behaviors, COPD and SCLCwarrants investigation to fa-
cilitate early detection of SCLC.
Funding
This work was supported by the National Institutes of Health and
National Cancer Institute (Grants CA092824, CA074386, CA090578,
ES00002, CA80127, CA84354, CA68384, the Intramural Research Pro-
gram, CA060691, HHSN261201000028C, P30CA022453, CA167462,
DA11386, CA90833, CA77954, CA09142, CA96134, and ES011667); BfS
(Bundesamt für Strahlenschutz, Germany) (Grant St. Sch 1066, 4074,
4074/1);Mayo Clinic Foundation; Canadian Cancer Society Research In-
stitute (Grant 020214); FIS/Spain (Grant FIS-01/310, FIS-PI03-0365,
and FIS-07-BI060604); FICYT/Asturias (Grants FICYT PB02-67 and
FICYT IB09-133); Roy Castle Lung Cancer Foundation in UK; Ministry
of Education, Science, Sports, Culture, and Technology of Japan
(Grants-in-Aid for Scientific Research on Priority and Innovative
Areas); Ministry of Health, Labor, and Welfare of Japan [Third-Term
Comprehensive 10-Year Strategy for Cancer Control]; National Cancer
Center Research and Development Fund (23-A-4); Health and Labor
Sciences Research Grants for Research on Applying Health Technology
from Ministry of Health, Labor and Welfare; the Bi-national Israel–US
Science Foundation; the Baden-WürttembergMinistry of Science Re-
search and Arts Foundation; the Ann Fitzpatrick Alper Research Pro-
gram for Environmental Genomics of the University of California at
Los Angeles Jonsson Comprehensive Cancer Center. Dr. Wei is par-
tially supported by the National Natural Science Foundation of
China (Grant 81402764) and the Natural Science Foundation of
Jiangsu, China (Grant BK20140907). Dr. Zhang is partially supported
by the National Natural Science Foundation of China (Grant No.
81402763).
1684 R. Huang et al. / EBioMedicine 2 (2015) 1677–1685Role of Sponsors
The sponsors of all the funding bodies had no role in the design of
the study, the collection and analysis of the data, or the preparation of
the manuscript.
Author Contributions
Dr. Ru-Yi Huang generated the conception, done the data analysis,
interpreted the data, andwrote themanuscript. Dr. YongyueWei gener-
ated the conception together with analyzing the data in depth and re-
vising the manuscript. Dr. Rayjean Hung was in charge of the data
harmonization, monitor of the consortium work and offered statistical
assistance for themanuscript. All authors from the ILCCO group contrib-
uted to the design and execution of thework and to the preparation and
drafting critically of this report. Additionally, all had the opportunity to
contribute to the interpretation of the results and to the redrafting of the
report. Approval of the final report was obtained from all authors. Dr.
David Christiani wrote and supervised the project concept and was
responsible for the final report.
Conflicts of Interest
We declare that we have no conflicts of interest.
Acknowledgments
We thank Dr. June Carroll and the Mount Sinai Hospital Granovsky
Gluskin Family Medicine Centre for helping with the recruitment of
the MSH-PMH study. We thank the study participants and the Lung
Cancer Study Team of the MGH Thoracic Oncology Center.
Appendix A Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.031.
References
Armstrong, B.G., Sloan, M., 1989. Ordinal regression models for epidemiologic data. Am.
J. Epidemiol. 129 (1), 191–204.
Ballaz, S., Mulshine, J.L., 2003. The potential contributions of chronic inflammation to lung
carcinogenesis. Clin. Lung Cancer 5 (1), 46–62.
Barr, R.G., Herbstman, J., Speizer, F.E., Camargo Jr., C.A., 2002. Validation of self-reported
chronic obstructive pulmonary disease in a cohort study of nurses. Am.
J. Epidemiol. 155 (10), 965–971.
Bednarek, M., Maciejewski, J., Wozniak, M., Kuca, P., Zielinski, J., 2008. Prevalence, severity
and underdiagnosis of COPD in the primary care setting. Thorax 63 (5), 402–407.
Brenner, D.R., Hung, R.J., Tsao, M.S., et al., 2010. Lung cancer risk in never-smokers: a pop-
ulation-based case–control study of epidemiologic risk factors. BMC Cancer 10, 285.
Campbell, I., 1996. Usefulness of generalized additive models. Stat. Methods Med. Res. 5
(3), 331–332.
Conway, M.R., 1990. A random effects model for binary data. Biometrics 46, 317–328.
Cote, M.L., Liu, M., Bonassi, S., et al., 2012. Increased risk of lung cancer in individuals with
a family history of the disease: a pooled analysis from the International Lung Cancer
Consortium. Eur. J. Cancer 48 (13), 1957–1968.
Eisner, M.D., Trupin, L., Katz, P.P., et al., 2005. Development and validation of a survey-
based COPD Severity Score. Chest 127 (6), 1890–1897.
Engeland, A., Haldorsen, T., Andersen, A., Tretli, S., 1996. The impact of smoking habits on
lung cancer risk: 28 years' observation of 26,000 Norwegianmen andwomen. Cancer
Causes Control 7 (3), 366–376.
Etzel, C.J., Lu, M., Merriman, K., Liu, M., Vaporciyan, A., Spitz, M.R., 2006. An epidemiologic
study of early onset lung cancer. Lung Cancer 52 (2), 129–134.
Fan, Y.G., Jiang, Y., Chang, R.S., et al., 2011. Prior lung disease and lung cancer risk in an
occupational-based cohort in Yunnan, China. Lung Cancer 72 (2), 258–263.
Field, J.K., Smith, D.L., Duffy, S., Cassidy, A., 2005. The Liverpool Lung Project Research pro-
tocol. Int. J. Oncol. 27 (6), 1633–1645.
Freedman, N.D., Leitzmann, M.F., Hollenbeck, A.R., Schatzkin, A., Abnet, C.C., 2008. Ciga-
rette smoking and subsequent risk of lung cancer in men and women: analysis of a
prospective cohort study. Lancet Oncol. 9 (7), 649–656.
Fruh, M., De Ruysscher, D., Popat, S., Crino, L., Peters, S., Felip, E., 2013. Small-cell lung can-
cer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann. Oncol. 24 (Suppl. 6), vi99–v105.van Gestel, Y.R., Hoeks, S.E., Sin, D.D., et al., 2009. COPD and cancer mortality: the influ-
ence of statins. Thorax 64 (11), 963–967.
Goodman, G.E., Valanis, B., Meyskens Jr., F.L., et al., 1998. Strategies for recruitment to a
population-based lung cancer prevention trial: the CARET experience with heavy
smokers. Beta-carotene and retinol efficacy trial. Cancer Epidemiol. Biomark. Prev. 7
(5), 405–412.
Hashibe, M., Morgenstern, H., Cui, Y., et al., 2006. Marijuana use and the risk of lung and
upper aerodigestive tract cancers: results of a population-based case–control study.
Cancer Epidemiol. Biomark. Prev. 15 (10), 1829–1834.
Hastie, T., Tibshirani, R., 1995. Generalized additive models for medical research. Stat.
Methods Med. Res. 4 (3), 187–196.
Heck, J.E., Andrew, A.S., Onega, T., et al., 2009. Lung cancer in a U.S. population with low to
moderate arsenic exposure. Environ. Health Perspect. 117 (11), 1718–1723.
Houghton, A.M., 2013. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer
13 (4), 233–245.
Houtmeyers, E., Gosselink, R., Gayan-Ramirez, G., Decramer, M., 1999. Regulation of
mucociliary clearance in health and disease. Eur. Respir. J. 13 (5), 1177–1188.
Hung, R.J., Christiani, D.C., Risch, A., et al., 2008. International Lung Cancer Consortium:
pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer
Epidemiol. Biomark. Prev. 17 (11), 3081–3089.
Ito, H., McKay, J.D., Hosono, S., et al., 2012. Association between a genome-wide associa-
tion study-identified locus and the risk of lung cancer in Japanese population.
J. Thorac. Oncol. 7 (5), 790–798.
Janda, S., Park, K., FitzGerald, J.M., Etminan, M., Swiston, J., 2009. Statins in COPD: a sys-
tematic review. Chest 136 (3), 734–743.
Kalemkerian, G.P., Akerley, W., Bogner, P., et al., 2013. Small cell lung cancer. J. Natl.
Compr. Cancer Netw. 11 (1), 78–98.
Kato, K., Kiyokawa, T., Mori, K., et al., 2011. Current state of treatment for advanced gastric
cancer. Gan To Kagaku Ryoho 38 (2), 184–186.
Kew, K.M., Seniukovich, A., 2014. Inhaled steroids and risk of pneumonia for chronic ob-
structive pulmonary disease. Cochrane Database Syst. Rev. 3, CD010115.
Kim, J.H., Hong, Y.C., 2013. No association between tumor necrosis factor-alpha gene poly-
morphisms and lung cancer risk. Environ. Health Toxicol. 28, e2013012.
Kreienbrock, L., Kreuzer, M., Gerken, M., et al., 2001. Case–control study on lung
cancer and residential radon in Western Germany. Am. J. Epidemiol. 153 (1),
42–52.
Lamprecht, B., Soriano, J.B., Studnicka, M., et al., 2015. Determinants of underdiagnosis of
COPD in national and international surveys. Chest.
Landi, M.T., Consonni, D., Rotunno, M., et al., 2008. Environment and genetics in lung can-
cer etiology (EAGLE) study: an integrative population-based case–control study of
lung cancer. BMC Public Health 8, 203.
Lee, C.H., Hyun, M.K., Jang, E.J., Lee, N.R., Kim, K., Yim, J.J., 2013. Inhaled corticosteroid use
and risks of lung cancer and laryngeal cancer. Respir. Med. 107 (8), 1222–1233.
Lee, S.M., Woll, P.J., Rudd, R., et al., 2009. Anti-angiogenic therapy using thalidomide com-
bined with chemotherapy in small cell lung cancer: a randomized, double-blind, pla-
cebo-controlled trial. J. Natl. Cancer Inst. 101 (15), 1049–1057.
Li, L., Clevers, H., 2010. Coexistence of quiescent and active adult stem cells in mammals.
Science 327 (5965), 542–545.
Liu, X., Engelhardt, J.F., 2008. The glandular stem/progenitor cell niche in airway develop-
ment and repair. Proc. Am. Thorac. Soc. 5 (6), 682–688.
Liu, H., Kho, A.T., Kohane, I.S., Sun, Y., 2006. Predicting survival within the lung cancer his-
topathological hierarchy using a multi-scale genomic model of development. PLoS
Med. 3 (7), e232.
Lopez-Cima, M.F., Alvarez-Avellon, S.M., Pascual, T., Fernandez-Somoano, A., Tardon, A.,
2012. Genetic polymorphisms in CYP1A1, GSTM1, GSTP1 and GSTT1 metabolic
genes and risk of lung cancer in Asturias. BMC Cancer 12, 433.
Loriot, M.A., Rebuissou, S., Oscarson, M., et al., 2001. Genetic polymorphisms of cyto-
chrome P450 2A6 in a case–control study on lung cancer in a French population.
Pharmacogenetics 11 (1), 39–44.
Luce, D., Stucker, I., 2011. Investigation of occupational and environmental causes of re-
spiratory cancers (ICARE): a multicenter, population-based case–control study in
France. BMC Public Health 11, 928.
Mannino, D.M., Gagnon, R.C., Petty, T.L., Lydick, E., 2000. Obstructive lung disease and
low lung function in adults in the United States: data from the National Health
and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 160 (11),
1683–1689.
Miller, D.P., Liu, G., De Vivo, I., et al., 2002. Combinations of the variant genotypes of
GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer
Res. 62 (10), 2819–2823.
Murgia, N., Brisman, J., Claesson, A., Muzi, G., Olin, A.C., Toren, K., 2014. Validity of a ques-
tionnaire-based diagnosis of chronic obstructive pulmonary disease in a general pop-
ulation-based study. BMC Pulm. Med. 14, 49.
Muscat, J.E., Stellman, S.D., Wynder, E.L., 1995. Insulation, asbestos, smoking habits, and
lung cancer cell types. Am. J. Ind. Med. 27 (2), 257–269.
Parimon, T., Chien, J.W., Bryson, C.L., McDonell, M.B., Udris, E.M., Au, D.H., 2007. Inhaled
corticosteroids and risk of lung cancer among patients with chronic obstructive pul-
monary disease. Am. J. Respir. Crit. Care Med. 175 (7), 712–719.
Park, J.Y., Chen, L., Elahi, A., Lazarus, P., Tockman, M.S., 2005. Genetic analysis of micro-
somal epoxide hydrolase gene and its association with lung cancer risk. Eur.
J. Cancer Prev. 14 (3), 223–230.
Pesch, B., Kendzia, B., Gustavsson, P., et al., 2012. Cigarette smoking and lung cancer–rel-
ative risk estimates for the major histological types from a pooled analysis of case–
control studies. Int. J. Cancer 131 (5), 1210–1219.
Pruefer, D., Makowski, J., Schnell, M., et al., 2002. Simvastatin inhibits inflammato-
ry properties of Staphylococcus aureus alpha-toxin. Circulation 106 (16),
2104–2110.
1685R. Huang et al. / EBioMedicine 2 (2015) 1677–1685Purdue, M.P., Gold, L., Jarvholm, B., Alavanja, M.C., Ward, M.H., Vermeulen, R., 2007. Im-
paired lung function and lung cancer incidence in a cohort of Swedish construction
workers. Thorax 62 (1), 51–56.
Raviv, S., Hawkins, K.A., DeCamp Jr., M.M., Kalhan, R., 2011. Lung cancer in chronic ob-
structive pulmonary disease: enhancing surgical options and outcomes. Am.
J. Respir. Crit. Care Med. 183 (9), 1138–1146.
Roca, M., Roca, I.C., Mihaescu, T., 2012. Lung cancer— a comorbidity in chronic obstructive
pulmonary disease. Rev. Med. Chir. Soc. Med. Nat. Iasi 116 (4), 1055–1062.
Ruano-Ravina, A., Figueiras, A., Barros-Dios, J.M., 2004. Type of wine and risk of lung can-
cer: a case–control study in Spain. Thorax 59 (11), 981–985.
Ruano-Ravina, A., Pereyra, M.F., Castro, M.T., Perez-Rios, M., Abal-Arca, J., Barros-Dios, J.M.,
2014. Genetic susceptibility, residential radon, and lung cancer in a radon prone area.
J. Thorac. Oncol. 9 (8), 1073–1080.
Schottker, B., Haug, U., Schomburg, L., et al., 2013. Strong associations of 25-
hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respira-
tory disease mortality in a large cohort study. Am. J. Clin. Nutr. 97 (4), 782–793.
Schwartz, A.G., Ruckdeschel, J.C., 2006. Familial lung cancer: genetic susceptibility and re-
lationship to chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 173
(1), 16–22.
Schwartz, A.G., Cote, M.L., Wenzlaff, A.S., Land, S., Amos, C.I., 2009. Racial differences in the
association between SNPs on 15q25.1, smoking behavior, and risk of non-small cell
lung cancer. J. Thorac. Oncol. 4 (10), 1195–1201.
Sevilya, Z., Leitner-Dagan, Y., Pinchev, M., et al., 2014. Low integrated DNA repair score
and lung cancer risk. Cancer Prev. Res. (Phila.) 7 (4), 398–406.
St Sauver, J.L., Grossardt, B.R., Leibson, C.L., Yawn, B.P., Melton 3rd, L.J., Rocca, W.A., 2012.
Generalizability of epidemiological findings and public health decisions: an illustra-
tion from the Rochester Epidemiology Project. Mayo Clin. Proc. 87 (2), 151–160.
Stang, A., Pohlabeln, H., Muller, K.M., Jahn, I., Giersiepen, K., Jockel, K.H., 2006. Diagnostic
agreement in the histopathological evaluation of lung cancer tissue in a population-
based case–control study. Lung Cancer 52 (1), 29–36.
Straus, S.E., McAlister, F.A., Sackett, D.L., Deeks, J.J., 2002. Accuracy of history, wheezing,
and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease.
J. Gen. Intern. Med. 17 (9), 684–688.Thorley, A.J., Tetley, T.D., 2007. Pulmonary epithelium, cigarette smoke, and chronic ob-
structive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2 (4), 409–428.
VanderWeele, T.J., Vansteelandt, S., 2010. Odds ratios for mediation analysis for a dichot-
omous outcome. Am. J. Epidemiol. 172 (12), 1339–1348.
VanderWeele, T.J., Asomaning, K., Tchetgen Tchetgen, E.J., et al., 2012. Genetic variants on
15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am.
J. Epidemiol. 175 (10), 1013–1020.
Vineis, P., Kogevinas, M., Simonato, L., Brennan, P., Boffetta, P., 2000. Levelling-off of
the risk of lung and bladder cancer in heavy smokers: an analysis based on
multicentric case–control studies and a metabolic interpretation. Mutat. Res.
463 (1), 103–110.
Wang, Y., McKay, J.D., Rafnar, T., et al., 2014. Rare variants of large effect in BRCA2 and
CHEK2 affect risk of lung cancer. Nat. Genet. 46 (7), 736–741.
Wang, J., Spitz, M.R., Amos, C.I., Wilkinson, A.V., Wu, X., Shete, S., 2010. Mediating ef-
fects of smoking and chronic obstructive pulmonary disease on the relation be-
tween the CHRNA5-A3 genetic locus and lung cancer risk. Cancer 116 (14),
3458–3462.
Yang, P., Allen, M.S., Aubry, M.C., et al., 2005. Clinical features of 5628 primary lung cancer
patients: experience at Mayo Clinic from 1997 to 2003. Chest 128 (1), 452–462.
Young, R.P., Hopkins, R.J., 2011. How the genetics of lung cancer may overlap with COPD.
Respirology 16 (7), 1047–1055.
Zhai, R., Yu, X., Shafer, A., Wain, J.C., Christiani, D.C., 2014b. The impact of coexisting COPD
on survival of patients with early-stage non-small cell lung cancer undergoing surgi-
cal resection. Chest 145 (2), 346–353.
Zhai, R., Yu, X., Wei, Y., Su, L., Christiani, D.C., 2014a. Smoking and smoking cessation in
relation to the development of co-existing non-small cell lung cancer with chronic
obstructive pulmonary disease. Int. J. Cancer 134 (4), 961–970.
Zhang, M., Hu, Z., Huang, J., et al., 2010. A 3'-untranslated region polymorphism in IGF1
predicts survival of non-small cell lung cancer in a Chinese population. Clin. Cancer
Res. 16 (4), 1236–1244.
